[go: up one dir, main page]

AR095832A1 - ORAL PHARMACEUTICAL COMPOSITION USEFUL FOR THE DISORDER OF THE ATTENTION AND HYPERACTIVITY DEFICIT, NUTRITIONAL SUPPLEMENT AND FOOD THAT UNDERSTAND IT AND PROCESS TO PREPARE COMPOSITION - Google Patents

ORAL PHARMACEUTICAL COMPOSITION USEFUL FOR THE DISORDER OF THE ATTENTION AND HYPERACTIVITY DEFICIT, NUTRITIONAL SUPPLEMENT AND FOOD THAT UNDERSTAND IT AND PROCESS TO PREPARE COMPOSITION

Info

Publication number
AR095832A1
AR095832A1 ARP140101549A ARP140101549A AR095832A1 AR 095832 A1 AR095832 A1 AR 095832A1 AR P140101549 A ARP140101549 A AR P140101549A AR P140101549 A ARP140101549 A AR P140101549A AR 095832 A1 AR095832 A1 AR 095832A1
Authority
AR
Argentina
Prior art keywords
oral pharmaceutical
disorder
attention
food
understand
Prior art date
Application number
ARP140101549A
Other languages
Spanish (es)
Inventor
Alejandro Fiore Esteban
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of AR095832A1 publication Critical patent/AR095832A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica oral utilizada para el trastorno del déficit de atención e hiperactividad, caracterizada por comprender una cantidad terapéuticamente efectiva de ácidos grasos Omega-3, una cantidad. terapéuticamente efectiva de hierro y una cantidad terapéuticamente efectiva de cinc junto a excipientes farmacéuticamente aceptables.Claim 1: An oral pharmaceutical composition used for attention deficit hyperactivity disorder, characterized by comprising a therapeutically effective amount of Omega-3 fatty acids, an amount. therapeutically effective iron and a therapeutically effective amount of zinc together with pharmaceutically acceptable excipients.

ARP140101549A 2013-04-23 2014-04-09 ORAL PHARMACEUTICAL COMPOSITION USEFUL FOR THE DISORDER OF THE ATTENTION AND HYPERACTIVITY DEFICIT, NUTRITIONAL SUPPLEMENT AND FOOD THAT UNDERSTAND IT AND PROCESS TO PREPARE COMPOSITION AR095832A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013004549A MX362730B (en) 2013-04-23 2013-04-23 Composition of omega-3 fatty acids, zinc and iron for the treatment of attention deficit hyperactivity disorder (adhd).

Publications (1)

Publication Number Publication Date
AR095832A1 true AR095832A1 (en) 2015-11-11

Family

ID=51792461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101549A AR095832A1 (en) 2013-04-23 2014-04-09 ORAL PHARMACEUTICAL COMPOSITION USEFUL FOR THE DISORDER OF THE ATTENTION AND HYPERACTIVITY DEFICIT, NUTRITIONAL SUPPLEMENT AND FOOD THAT UNDERSTAND IT AND PROCESS TO PREPARE COMPOSITION

Country Status (4)

Country Link
AR (1) AR095832A1 (en)
BR (1) BR112015026764A2 (en)
MX (1) MX362730B (en)
WO (1) WO2014174468A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
DE202007000949U1 (en) * 2007-01-23 2007-04-12 Vogel Lukas Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials

Also Published As

Publication number Publication date
WO2014174468A3 (en) 2014-12-31
WO2014174468A2 (en) 2014-10-30
MX2013004549A (en) 2014-10-23
MX362730B (en) 2019-02-05
BR112015026764A2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
PH12016501194B1 (en) Lipid comprising long chain polyunsaturated fatty acids
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
ES2666322T3 (en) Pharmaceutical compositions for the treatment of muscular disorders
CL2018001705A1 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant.
UA114615C2 (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX2015009104A (en) Solid solution compositions and use in cardiovascular disease.
MX367521B (en) FAST-ACTING INSULIN COMPOSITIONS.
MX2014000770A (en) Fatty acid compositions.
PE20150092A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
CY1122248T1 (en) MIXTURE OF FATTY ACIDS FOR USE IN THE THERAPEUTIC TREATMENT OF INFLAMMATORY DISEASES
BR112015030268A2 (en) pharmaceutical composition, container, kit, and method for preparing a composition
CL2017001516A1 (en) Feed supplement material for use in aquaculture feed.
MX2015015630A (en) Use of tall oil fatty acid.
MX2016011290A (en) Lipoic acid choline ester compositions and methods of use.
MX2017000676A (en) ORITAVANCINA HIGH PURITY AND METHOD TO PRODUCE THE SAME.
MA40417A (en) Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
CL2016001786A1 (en) Regulation of ornithine metabolism to manipulate the mannose-rich glycoform content of recombinant proteins.
MX377579B (en) ORAL PHARMACEUTICAL COMPOSITION OF LOW DOSE ISOTRETINOIN AND ITS PREPARATION PROCESS.
MX2021001790A (en) Solid compositions of triglycerides and uses thereof.
AR100028A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING ESTEARIDÓNIC ACID
BR112016028561A8 (en) composition and dosage form comprising a marine oil comprising fatty acids, and use thereof
MA40447A (en) Oral pharmaceutical composition of isotretinoin
CO2017005911A2 (en) Method to increase levels of omega-3 fatty acids in beef products through the administration of a diet of grass and seaweed
PH12016502311A1 (en) Omega-3 analogues
AR093252A1 (en) ORAL PHARMACEUTICAL COMPOSITION USED AS ANTIPARASITARY AND ANTIDIARRICS AND PROCESSES TO PREPARE IT

Legal Events

Date Code Title Description
FC Refusal